Form 4: Veradigm Director David B. Stevens Receives Significant RSU Grant

Veradigm Inc. Director David B. Stevens was granted 46,512 restricted stock units as part of the company's 2024 Stock Incentive Plan, increasing his total beneficial ownership to 121,002 shares.

Summary

• David B. Stevens, a Director of Veradigm Inc. (MDRX), acquired 46,512 shares of common stock on June 2, 2025.
• The acquisition was an award of Restricted Stock Units (RSUs) granted under the Veradigm, Inc. Amended and Restated 2024 Stock Incentive Plan.
• Each RSU was valued at $4.3 per share at the time of grant.
• The granted RSUs will vest 100% on the first anniversary of the Grant Date, which is June 2, 2026.
• Following this transaction, Mr. Stevens' beneficial ownership of Veradigm common stock increased to 121,002 shares.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive signal as it aligns management's interests with shareholders, indicating confidence in the company's future performance. It is a routine compensation event rather than a direct cash investment, hence not a 'strong buy' signal, but generally favorable.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction indicates the company's ongoing commitment to equity-based compensation plans to attract and retain key personnel.

Future Outlook

The future outlook for David B. Stevens' ownership includes the vesting of the 46,512 Restricted Stock Units on June 2, 2026, which will convert into common stock, further increasing his direct beneficial ownership.

Industry Context

The grant of Restricted Stock Units is a common practice in the healthcare technology and software industry for executive and director compensation, aiming to incentivize long-term performance and align interests with shareholders. This is a standard mechanism for public companies to compensate their board members.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation is a widely adopted practice across various industries, including healthcare IT, and is consistent with global benchmarks for executive and director remuneration.
• The vesting schedule of 100% on the first anniversary of the grant date is a common structure for director RSU awards, similar to practices observed at comparable companies in the software and healthcare sectors.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to David B. Stevens, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially leading to decisions that enhance shareholder value.
• Employees: While not directly impacting employees, the use of equity compensation plans can signal a commitment to performance-based incentives within the company culture.

Next Steps

• The 46,512 Restricted Stock Units granted to David B. Stevens are scheduled to vest on June 2, 2026.

Key Dates

Recommendation

Keywords

Veradigm, MDRX, Form 4, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Beneficial Ownership, Director Compensation, Stock Incentive Plan